Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% below its 5-year average of 0.01, near the high end of its 5-year range (-3.91–0.05).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% above its 12-month average of -0.78.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
-0.78
DEBT TO EQUITY RATIO AVG 3Y
0.01
DEBT TO EQUITY RATIO AVG 5Y
0.01
DEBT TO EQUITY RATIO AVG 10Y
0.01
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 641 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Indaptus Therapeutics, Inc.
Market Cap
$285.37M
Debt to Equity Ratio
0.00
TTM Avg
-0.78
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$284.21M
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.04
5Y Avg
0.03
Market Cap
$288.40M
Debt to Equity Ratio
0.16
TTM Avg
0.34
3Y Avg
0.33
5Y Avg
0.27
Market Cap
$289.76M
Debt to Equity Ratio
0.05
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.50
Market Cap
$280.29M
Debt to Equity Ratio
0.04
TTM Avg
0.11
3Y Avg
0.22
5Y Avg
0.26
Market Cap
$289.63M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$277.99M
Debt to Equity Ratio
0.49
TTM Avg
0.33
3Y Avg
0.29
5Y Avg
0.26
Market Cap
$274.62M
Debt to Equity Ratio
0.07
TTM Avg
0.07
3Y Avg
0.06
5Y Avg
0.07
Market Cap
$296.13M
Debt to Equity Ratio
0.04
TTM Avg
0.04
3Y Avg
0.05
5Y Avg
0.06
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | $285.37M | 0.00 | -0.78 | 0.01 | 0.01 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $284.21M | 0.02 | 0.03 | 0.04 | 0.03 |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.40M | 0.16 | 0.34 | 0.33 | 0.27 |
| Standard BioTools Inc. (LAB)vs › | $289.76M | 0.05 | 0.07 | 0.07 | 0.50 |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | 0.04 | 0.11 | 0.22 | 0.26 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $289.63M | 0.01 | 0.01 | 0.01 | 0.01 |
| Fate Therapeutics, Inc. (FATE)vs › | $277.99M | 0.49 | 0.33 | 0.29 | 0.26 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | 0.07 | 0.07 | 0.06 | 0.07 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $296.13M | 0.04 | 0.04 | 0.05 | 0.06 |
| Benitec Biopharma Inc. (BNTC)vs › | $301.43M | 0.00 | 0.01 | 0.70 | 0.51 |
Debt/Equity
0.00
Current Ratio
19.48
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | -3.91 |
| 2025-03-31 | 0.02 |
| 2024-12-31 | 0.02 |
| 2024-09-30 | 0.02 |
| 2024-06-30 | 0.02 |
| 2024-03-31 | 0.02 |
| 2023-12-31 | 0.01 |
| 2023-09-30 | 0.01 |
| 2023-06-30 | 0.01 |
| 2023-03-31 | 0.01 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.05 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.00 |
| 2020-09-30 | 0.06 |
| 2020-06-30 | 0.07 |
| 2020-03-31 | 0.08 |
| 2019-12-31 | 0.12 |
| 2019-09-30 | 0.04 |
| 2019-06-30 | 0.02 |
| 2019-03-31 | 0.01 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-30 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-30 | 0.00 |
